journal
MENU ▼
Read by QxMD icon Read
search

Multiple Sclerosis: Clinical and Laboratory Research

journal
https://www.readbyqxmd.com/read/29781383/preferential-spinal-cord-volume-loss-in-primary-progressive-multiple-sclerosis
#1
Charidimos Tsagkas, Stefano Magon, Laura Gaetano, Simon Pezold, Yvonne Naegelin, Michael Amann, Christoph Stippich, Philippe Cattin, Jens Wuerfel, Oliver Bieri, Till Sprenger, Ludwig Kappos, Katrin Parmar
BACKGROUND: Little is known on longer term changes of spinal cord volume (SCV) in primary progressive multiple sclerosis (PPMS). OBJECTIVE: Longitudinal evaluation of SCV loss in PPMS and its correlation to clinical outcomes, compared to relapse-onset multiple sclerosis (MS) subtypes. METHODS: A total of 60 MS age-, sex- and disease duration-matched patients (12 PPMS, each 24 relapsing-remitting (RRMS) and secondary progressive MS (SPMS)) were analysed annually over 6 years of follow-up...
May 1, 2018: Multiple Sclerosis: Clinical and Laboratory Research
https://www.readbyqxmd.com/read/29775164/the-clinical-value-of-the-patient-reported-multiple-sclerosis-neuropsychological-screening-questionnaire
#2
Ilse M Nauta, Lisanne J Balk, Judith M Sonder, Hanneke E Hulst, Bernard Mj Uitdehaag, Luciano Fasotti, Brigit A de Jong
BACKGROUND: Cognitive problems are difficult to identify in patients with multiple sclerosis (MS). OBJECTIVE: To investigate the clinical applicability of the patient-reported MS Neuropsychological Screening Questionnaire (MSNQ-P). METHODS: Cut-off scores were determined to differentiate between cognitively impaired ( n = 90), mildly cognitively impaired ( n = 115), and cognitively preserved ( n = 147) MS patients using receiver operating characteristic analyses...
May 1, 2018: Multiple Sclerosis: Clinical and Laboratory Research
https://www.readbyqxmd.com/read/29775134/csf-inflammatory-biomarkers-responsive-to-treatment-in-progressive-multiple-sclerosis-capture-residual-inflammation-associated-with-axonal-damage
#3
Jeppe Romme Christensen, Mika Komori, Marina Rode von Essen, Rikke Ratzer, Lars Börnsen, Bibi Bielekova, Finn Sellebjerg
BACKGROUND: Development of treatments for progressive multiple sclerosis (MS) is challenged by the lack of sensitive and treatment-responsive biomarkers of intrathecal inflammation. OBJECTIVE: To validate the responsiveness of cerebrospinal fluid (CSF) inflammatory biomarkers to treatment with natalizumab and methylprednisolone in progressive MS and to examine the relationship between CSF inflammatory and tissue damage biomarkers. METHODS: CSF samples from two open-label phase II trials of natalizumab and methylprednisolone in primary and secondary progressive MS...
May 1, 2018: Multiple Sclerosis: Clinical and Laboratory Research
https://www.readbyqxmd.com/read/29774781/aging-and-lymphocyte-changes-by-immunomodulatory-therapies-impact-pml-risk-in-multiple-sclerosis-patients
#4
Elizabeth A Mills, Yang Mao-Draayer
New potent immunomodulatory therapies for multiple sclerosis (MS) are associated with increased risk for progressive multifocal leukoencephalopathy (PML). It is unclear why a subset of treated patients develops PML, but patient age has emerged as an important risk factor. PML is caused by the JC virus and aging is associated with immune senescence, which increases susceptibility to infection. With the goal of improving PML risk stratification, we here describe the lymphocyte changes that occur with disease-modifying therapies (DMTs) associated with high or moderate risk toward PML in MS patients, how these changes compare to immune aging, and which measures best correlate with risk...
May 1, 2018: Multiple Sclerosis: Clinical and Laboratory Research
https://www.readbyqxmd.com/read/29774770/high-neurofilament-levels-are-associated-with-clinically-definite-multiple-sclerosis-in-children-and-adults-with-clinically-isolated-syndrome
#5
Roos M van der Vuurst de Vries, Yu Yi M Wong, Julia Y Mescheriakova, E Daniëlle van Pelt, Tessel F Runia, Naghmeh Jafari, Theodora Am Siepman, Marie-José Melief, Annet F Wierenga-Wolf, Marvin M van Luijn, Johnny P Samijn, Rinze F Neuteboom, Rogier Q Hintzen
BACKGROUND: A promising biomarker for axonal damage early in the disease course of multiple sclerosis (MS) is neurofilament light chain (NfL). It is unknown whether NfL has the same predictive value for MS diagnosis in children as in adults. OBJECTIVE: To explore the predictive value of NfL levels in cerebrospinal fluid (CSF) for MS diagnosis in paediatric and adult clinically isolated syndrome (CIS) patients. METHODS: A total of 88 adult and 65 paediatric patients with a first attack of demyelination were included and followed (mean follow up-time in adults: 62...
May 1, 2018: Multiple Sclerosis: Clinical and Laboratory Research
https://www.readbyqxmd.com/read/29771191/pure-spinal-multiple-sclerosis-a-possible-novel-entity-within-the-multiple-sclerosis-disease-spectrum
#6
Jie Ping Schee, Shanthi Viswanathan
We identified five female patients retrospectively with relapsing short-segment partial myelitis whose clinical and paraclinical features were suggestive of cord involvement of multiple sclerosis (MS)-type albeit not rigidly fulfilling the 2017 McDonald criteria. Notably, these patients had not developed any typical MS-like brain lesions despite repeated neuroimaging assessments over years. Comprehensive work-up for differential diagnoses of MS and other causes of transverse myelitis particularly neuromyelitis optica spectrum disorders had been consistently negative on longitudinal follow-up...
May 1, 2018: Multiple Sclerosis: Clinical and Laboratory Research
https://www.readbyqxmd.com/read/29771186/cross-modal-plasticity-among-sensory-networks-in-neuromyelitis-optica-spectrum-disorders
#7
Maria Assunta Rocca, Filippo Savoldi, Paola Valsasina, Marta Radaelli, Paolo Preziosa, Giancarlo Comi, Andrea Falini, Massimo Filippi
OBJECTIVE: To explore resting-state (RS) functional connectivity (FC) of the main sensory/motor networks of patients with neuromyelitis optica spectrum disorders (NMOSDs), clinically isolated optic neuritis (ON), and myelitis. METHODS: Clinical evaluation and RS fMRI were obtained from 28 NMOSD, 11 recurrent ON, and 12 recurrent myelitis patients and 30 healthy controls. Between-group RS FC comparisons and correlations with motor performance were assessed (SPM12) on the main sensory/motor RS networks (RSNs) identified by independent component analysis...
May 1, 2018: Multiple Sclerosis: Clinical and Laboratory Research
https://www.readbyqxmd.com/read/29770725/infections-seem-to-be-more-frequent-before-onset-of-pediatric-multiple-sclerosis-a-danish-nationwide-nested-case-control-study
#8
Magnus Spangsberg Boesen, Nils Koch-Henriksen, Lau Caspar Thygesen, Frank Eriksson, Gorm Greisen, Alfred Peter Born, Morten Blinkenberg, Peter Vilhelm Uldall, Melinda Magyari
BACKGROUND: Infections are suspected environmental triggers for multiple sclerosis (MS). The relationship between the timing and cumulative number of childhood infections regarding pediatric MS risk is uninvestigated. OBJECTIVES: To investigate whether childhood infections contribute to pediatric MS. METHODS: A nationwide nested case-control study with detailed MS case ascertainment including chart review was undertaken. For each MS case, we selected five control children using density sampling from the entire Danish population, matching controls to children with MS by sex and birthdate...
May 1, 2018: Multiple Sclerosis: Clinical and Laboratory Research
https://www.readbyqxmd.com/read/29762081/reliability-and-acceptability-of-the-multiple-sclerosis-quality-of-life-29-questionnaire-in-an-english-speaking-cohort
#9
Georgina Baker, Krishnan Padmakumari Sivaraman Nair, Kathleen Baster, Rosalba Rosato, Alessandra Sloari
BACKGROUND: Multiple Sclerosis Quality-of-Life Questionnaire-54 (MSQoL-54) is a disease-specific instrument for assessing health-related quality of life (HRQoL). Due to the number of items, the time taken to complete it is long. A shorter 29-item version, Multiple Sclerosis Quality-of-Life Questionnaire-29 (MSQoL-29) is yet to be evaluated in English. OBJECTIVE: To assess reliability and acceptability of English version of MSQoL-29. METHODS: Among 100 participants with MS who first completed both MSQoL-54 and MSQoL-29, 91 completed MSQoL-29 after 4-8 weeks...
May 1, 2018: Multiple Sclerosis: Clinical and Laboratory Research
https://www.readbyqxmd.com/read/29762077/impact-of-the-2017-revisions-to-mcdonald-criteria-on-the-diagnosis-of-multiple-sclerosis
#10
Rebecca Beesley, Valerie Anderson, Katharine E Harding, Fady Joseph, Valentina Tomassini, Trevor P Pickersgill, Neil P Robertson, Emma C Tallantyre
No abstract text is available yet for this article.
May 1, 2018: Multiple Sclerosis: Clinical and Laboratory Research
https://www.readbyqxmd.com/read/29761738/emsqol-29-prospective-validation-of-the-abbreviated-electronic-version-of-msqol-54
#11
Rosalba Rosato, Silvia Testa, Antonio Bertolotto, Francesco Scavelli, Ambra M Giovannetti, Paolo Confalonieri, Francesco Patti, Clara Grazia Chisari, Alessandra Lugaresi, Erika Pietrolongo, Maria Grazia Grasso, Ilaria Rossi, Anna Toscano, Barbara Loera, Andrea Giordano, Alessandra Solari
BACKGROUND: We recently devised a shortened version of the 54-item Multiple Sclerosis Quality of Life (MSQOL-54) in paper (MSQOL-29, consisting of 25 items forming 7 subscales and 4 single items, and one filter question for 3 'sexual function' items) and electronic format (eMSQOL-29). OBJECTIVES: To prospectively assess eMSQOL-29 psychometric properties, acceptability/equivalence versus MSQOL-29. METHODS: Multiple sclerosis (MS) patients ( n = 623; Expanded Disability Status Scale (EDSS) range 0...
May 1, 2018: Multiple Sclerosis: Clinical and Laboratory Research
https://www.readbyqxmd.com/read/29761737/predictive-validity-of-neda-in-the-16-and-21-year-follow-up-from-the-pivotal-trial-of-interferon-beta-1b
#12
Douglas S Goodin, Anthony T Reder, Anthony L Traboulsee, David Kb Li, Dawn Langdon, Gary Cutter, Stuart Cook, Timothy O'Donnell, Marcelo Kremenchutzky, Joel Oger, Ralf Koelbach, Christoph Pohl, Eva-Maria Wicklein
BACKGROUND: Long-term follow-up from the randomized trial of interferon beta-1b (IFNB-1b) permitted the assessment of different definitions of no evidence of disease activity (NEDA) for predicting long-term outcome in multiple sclerosis (MS). OBJECTIVE: To examine the predictive validity of different NEDA definitions. METHODS: Predictive validity for negative disability outcomes (NDOs) at 16 years and survival at 21 years post-randomization were assessed...
May 1, 2018: Multiple Sclerosis: Clinical and Laboratory Research
https://www.readbyqxmd.com/read/29761736/treating-neuromyelitis-optica-with-azathioprine-20-year-clinical-practice
#13
Denis Bernardi Bichuetti, Marília Mamprim de Moraes Perin, Nilton Amorim de Souza, Enedina Maria Lobato de Oliveira
BACKGROUND: Neuromyelitis optica leads to severe disability. Preventive treatment includes steroids and immunosuppressants, and indications are based on retrospective and observational studies. METHODS: We analyzed 158 patients with neuromyelitis optica regarding disease course, prognostic factors, and treatment response to azathioprine, a widely available low-cost drug. Disability accumulation was used as an endpoint to treatment response. RESULTS: Eight patients with monophasic and 150 with relapsing disease with a median 7 years of disease duration and 4...
May 1, 2018: Multiple Sclerosis: Clinical and Laboratory Research
https://www.readbyqxmd.com/read/29761722/a-multicenter-randomized-controlled-trial-of-two-group-education-programs-for-fatigue-in-multiple-sclerosis-long-term-12-month-follow-up-at-one-site
#14
Cinda L Hugos, Michelle H Cameron, Zunqiu Chen, Yiyi Chen, Dennis Bourdette
BACKGROUND: A four-site RCT of Fatigue: Take Control (FTC), a multicomponent group program, found no significant differences from a control program, MS: Take Control (MSTC), in fatigue on the Modified Fatigue Impact Scale (MFIS) through 6 months. OBJECTIVE: Assess FTC for a delayed effect on fatigue. METHODS: Of 78 subjects at one site, 74 randomized to FTC or MSTC completed the MFIS at 12 months. RESULTS: Compared to baseline, FTC produced greater improvements in MFIS scores than MSTC (FTC -8...
May 1, 2018: Multiple Sclerosis: Clinical and Laboratory Research
https://www.readbyqxmd.com/read/29754529/much-if-not-all-of-the-cortical-damage-in-ms-can-be-attributed-to-the-microglial-cell-no
#15
Ranjan Dutta, Bruce D Trapp
No abstract text is available yet for this article.
May 1, 2018: Multiple Sclerosis: Clinical and Laboratory Research
https://www.readbyqxmd.com/read/29754520/much-if-not-all-of-the-cortical-damage-in-ms-can-be-attributed-to-the-microglial-cell-yes
#16
Thecla A van Wageningen, Anne-Marie van Dam
No abstract text is available yet for this article.
May 1, 2018: Multiple Sclerosis: Clinical and Laboratory Research
https://www.readbyqxmd.com/read/29754502/much-if-not-all-of-the-cortical-damage-in-ms-can-be-attributed-to-the-microglial-cell-commentary
#17
Jonathan I Spencer, Gabriele C DeLuca
No abstract text is available yet for this article.
May 1, 2018: Multiple Sclerosis: Clinical and Laboratory Research
https://www.readbyqxmd.com/read/29741124/clinical-commentary-on-late-onset-neutropenia-and-neurological-relapse-during-long-term-rituximab-therapy-in-mog-antibody-spectrum-disorder
#18
Yael Hacohen, Wallace J Brownlee
No abstract text is available yet for this article.
May 1, 2018: Multiple Sclerosis: Clinical and Laboratory Research
https://www.readbyqxmd.com/read/29741120/late-onset-neutropenia-and-neurological-relapse-during-long-term-rituximab-therapy-in-myelin-oligodendrocyte-glycoprotein-antibody-spectrum-disorder
#19
Damien Biotti, Fleur Lerebours, Fabrice Bonneville, Jonathan Ciron, Michel Clanet, David Brassat
Late-onset neutropenia after rituximab therapy (LONART) is defined as a fall in the absolute neutrophil count below 500/mm3 at least 3 weeks after rituximab infusion, in the absence of any other explanation. LONART is rare during dysimmune conditions but can be life-threatening. We report on two patients with LONART and associated neurological relapse occurring in myelin oligodendrocyte glycoprotein (MOG)-antibody spectrum disorders. Rituximab was reintroduced in one patient, while the second patient was switched to tocilizumab...
May 1, 2018: Multiple Sclerosis: Clinical and Laboratory Research
https://www.readbyqxmd.com/read/29722639/efficacy-of-rituximab-in-refractory-rrms
#20
Pierre Durozard, Adil Maarouf, Clémence Boutiere, Aurelie Ruet, Bruno Brochet, Sandra Vukusic, Clarisse Carra-Dalliere, Pierre Labauge, Guillaume Mathey, Marc Debouverie, Caroline Papeix, Elisabeth Maillart, Catherine Lubetzki, Caroline Bensa, Olivier Gout, Claire Giannesini, Bruno Stankoff, Jonathan Ciron, David Brassat, Jean Pelletier, Audrey Rico Lamy, Bertrand Audoin
OBJECTIVE: To investigate the efficacy of rituximab as rescue therapy in patients with relapsing-remitting multiple sclerosis (RRMS) and persistent disease activity confirmed by magnetic resonance imaging (MRI) despite immunosuppressive disease-modifying therapy (DMT). METHODS: In this observational nationwide retrospective multicenter study, we first identified 351 off-label rituximab-treated patients through a cohort of 15,984 RRMS patients. In this group, we identified patients with disease activity prior to rituximab confirmed by MRI (one or more new T2 lesion and/or gadolinium-enhancing lesion) despite immunosuppressive DMT (fingolimod, natalizumab, or mitoxantrone) with a follow-up after rituximab initiation longer than 6 months...
May 1, 2018: Multiple Sclerosis: Clinical and Laboratory Research
journal
journal
32305
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"